|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
|
US5356806A
(en)
|
1987-06-05 |
1994-10-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immortalized human cell lines containing exogenous cytochrome P450
|
|
US4937190A
(en)
|
1987-10-15 |
1990-06-26 |
Wisconsin Alumni Research Foundation |
Translation enhancer
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
JPH08511507A
(ja)
|
1993-03-08 |
1996-12-03 |
ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション |
哺乳動物宿主の結合組織を処置するための遺伝子導入
|
|
US5573764A
(en)
*
|
1994-01-21 |
1996-11-12 |
Genetics Institute, Inc. |
Use of interleukin-12 to prevent graft versus host disease
|
|
ATE200105T1
(de)
|
1994-05-13 |
2001-04-15 |
Chiron Corp |
Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
|
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
|
US5892071A
(en)
|
1994-09-30 |
1999-04-06 |
The Reagents Of The University Of California |
Cationic transport reagents
|
|
US5527928A
(en)
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
|
US5962424A
(en)
|
1995-02-21 |
1999-10-05 |
Arch Development Corporation |
Methods and compositions for targeting selectins
|
|
DK0811073T3
(da)
|
1995-02-24 |
2007-05-21 |
Univ Pennsylvania |
Avendelse af immunmodulatorer til fremstilling af medikamenter til inhibering af immunresponser mod co-administrerede rekombinanter
|
|
US5869715A
(en)
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
|
US5952221A
(en)
|
1996-03-06 |
1999-09-14 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a first and second nucleic acid sequence
|
|
US5994104A
(en)
|
1996-11-08 |
1999-11-30 |
Royal Free Hospital School Of Medicine |
Interleukin-12 fusion protein
|
|
JP2002506651A
(ja)
|
1998-03-16 |
2002-03-05 |
イントロジェン・セラピューティクス，インコーポレイテッド |
多重遺伝子ベクター
|
|
WO2000034309A1
(en)
*
|
1998-12-04 |
2000-06-15 |
Dana-Farber Cancer Institute, Inc. |
Cloning and characterization of a cd2 binding protein (cd2bp2)
|
|
US20030035790A1
(en)
|
1999-01-15 |
2003-02-20 |
Shu-Hsia Chen |
Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
|
|
AU3004700A
(en)
|
1999-02-24 |
2000-09-14 |
University Of Iowa Research Foundation, The |
Methods and compositions for delivery of and specific immune response to nucleotide expression systems
|
|
WO2001012234A1
(en)
|
1999-08-16 |
2001-02-22 |
Uab Research Foundation |
Gene transfer imaging and uses thereof
|
|
US6544780B1
(en)
|
2000-06-02 |
2003-04-08 |
Genphar, Inc. |
Adenovirus vector with multiple expression cassettes
|
|
EP1290206A2
(en)
|
2000-06-09 |
2003-03-12 |
University of Florida |
Recombinant aav vectors for gene therapy of obesity
|
|
AUPR069500A0
(en)
|
2000-10-11 |
2000-11-09 |
Coster, Douglas John |
Tissue modification
|
|
WO2002049501A2
(en)
|
2000-12-18 |
2002-06-27 |
Board Of Regents, University Of Texas System |
Local regional chemotherapy and radiotherapy using in situ hydrogel
|
|
US20030147853A1
(en)
|
2001-03-14 |
2003-08-07 |
Mcclelland Alan |
Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions
|
|
JP5089847B2
(ja)
|
2001-03-27 |
2012-12-05 |
ニューヨーク・ユニバーシティ |
アルファウイルスに基づく高親和性ラミニン受容体標的化ベクターを用いた腫瘍の治療
|
|
WO2002089658A2
(en)
|
2001-05-07 |
2002-11-14 |
New York University |
Microvascular free flaps for local or systemic delivery
|
|
CA2448120A1
(en)
|
2001-05-24 |
2002-11-28 |
Genzyme Corporation |
Muscle-specific expression vectors
|
|
AU2002316199A1
(en)
|
2001-06-08 |
2002-12-23 |
Children's Hospital Research Foundation |
Regulation of transgene expression following aav transduction
|
|
US20060292117A1
(en)
|
2002-04-17 |
2006-12-28 |
Loiler Scott A |
Improved rAAv vectors
|
|
AU2003221745A1
(en)
|
2002-04-19 |
2003-11-03 |
University Of Florida |
rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
|
|
US8802080B2
(en)
|
2002-05-01 |
2014-08-12 |
University Of Florida Research Foundation, Inc. |
Raav expression systems for genetic modification of specific capsid proteins
|
|
EP1618201A1
(en)
|
2003-05-01 |
2006-01-25 |
University of Florida Research Foundation, Inc. |
Vp2 - modified raav vectors and uses thereof
|
|
KR20060031610A
(ko)
|
2003-05-30 |
2006-04-12 |
유니버시티 오브 사우스 플로리다 |
악성 종양 치료 방법
|
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
UA92913C2
(ru)
*
|
2005-06-20 |
2010-12-27 |
Кадила Хелткере Лимитед |
Экспрессионный вектор и способы продуцирования высоких уровней белков
|
|
DE102005055128B4
(de)
|
2005-11-15 |
2015-04-02 |
Universität Rostock |
Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
|
|
US7833754B2
(en)
*
|
2006-01-13 |
2010-11-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
IL-12 for expression in mammalian cell
|
|
WO2007090125A2
(en)
|
2006-01-30 |
2007-08-09 |
Introgen Therapeutics, Inc. |
Prognostic factors for anti-hyperproliferative disease gene therapy
|
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
EP2016090A4
(en)
|
2006-04-26 |
2010-07-28 |
Int Aids Vaccine Initiative |
GENETIC ADJUVANCIES FOR VIRAL VACCINES
|
|
US9198984B2
(en)
|
2006-04-28 |
2015-12-01 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for AAV
|
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
WO2008128251A1
(en)
|
2007-04-17 |
2008-10-23 |
The Children's Hospital Of Philadelphia |
Humanized viral vectors and methods of use thereof
|
|
KR100911624B1
(ko)
*
|
2007-05-14 |
2009-08-12 |
연세대학교 산학협력단 |
Ｉｌ－１２ 및 ｉｌ－２３의 효율적인 공동발현 방법
|
|
US20110002961A1
(en)
|
2008-03-03 |
2011-01-06 |
Paul Hermonat Hermonat |
Interleukin 12 paracrine gene delivery enhanced CTL immunotherapy
|
|
KR101361416B1
(ko)
|
2008-10-08 |
2014-02-21 |
인트렉손 코포레이션 |
다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
|
|
AU2010241864B2
(en)
|
2009-04-30 |
2014-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
|
BR112012010755A2
(pt)
|
2009-11-05 |
2015-09-22 |
Proyecto Biomedicina Cima Sl |
constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
|
|
US20130195800A1
(en)
|
2010-03-23 |
2013-08-01 |
Intrexon Corporation |
Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
|
|
US9453241B2
(en)
*
|
2010-05-04 |
2016-09-27 |
Wayne State University |
AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
|
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
|
CA2850575C
(en)
|
2011-10-11 |
2020-12-15 |
Universitat Zurich Prorektorat Mnw |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
|
SG11201404741VA
(en)
|
2012-02-07 |
2014-09-26 |
Global Bio Therapeutics Usa Inc |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
|
KR102057540B1
(ko)
|
2012-02-17 |
2019-12-19 |
더 칠드런스 호스피탈 오브 필라델피아 |
세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법
|
|
PT3024498T
(pt)
|
2013-07-22 |
2020-03-06 |
Childrens Hospital Philadelphia |
Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos
|
|
EP3906939A1
(en)
*
|
2013-10-11 |
2021-11-10 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Epstein-barr virus vaccines
|
|
CA2933868A1
(en)
|
2013-12-18 |
2015-06-25 |
Intrexon Corporation |
Single chain il-12 nucleic acids, polypeptides, and uses thereof
|
|
EP3117002B1
(en)
*
|
2014-03-11 |
2025-12-03 |
Wayne State University |
A modified mglur6 promoter and methods of use
|
|
US10563222B2
(en)
*
|
2014-06-18 |
2020-02-18 |
Agency For Science, Technology And Research |
Promoters for high level expression
|
|
CN107207597A
(zh)
*
|
2014-11-06 |
2017-09-26 |
儿研所儿童医学中心 |
用于癌症和自身免疫疾病的免疫疗法
|
|
SG11201805162VA
(en)
|
2015-12-18 |
2018-07-30 |
Oncosec Medical Inc |
Plasmid constructs for heterologous protein expression and methods of use
|
|
DK3458083T5
(da)
|
2016-05-18 |
2024-10-21 |
Modernatx Inc |
Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
|
|
WO2018026872A1
(en)
*
|
2016-08-01 |
2018-02-08 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
|
US20190209652A1
(en)
*
|
2016-09-23 |
2019-07-11 |
Oncosec Medical Incorporated |
Modulating responses to checkpoint inhibitor therapy
|
|
EP3519436A4
(en)
|
2016-09-30 |
2020-09-09 |
Baylor College of Medicine |
TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
|
|
CN110267978A
(zh)
|
2016-10-07 |
2019-09-20 |
得克萨斯大学体系董事会 |
用于治疗癌症的表达膜锚定的il-12的t细胞
|
|
RU2742726C2
(ru)
*
|
2016-12-09 |
2021-02-10 |
Генемедицине Ко., Лтд. |
Противораковая композиция, содержащая рекомбинантный аденовирус, экспрессирующий разрушающий фактор для внеклеточного матрикса
|
|
FI3568483T3
(fi)
|
2017-01-10 |
2025-11-21 |
Childrens Medical Res Institute |
Polynukleotideja ja vektoreita siirtogeenien ilmentämiseen
|
|
UY37636A
(es)
*
|
2017-03-21 |
2018-10-31 |
Univ Muenchen Ludwig Maximilians |
Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1
|
|
CN116392609A
(zh)
*
|
2017-03-23 |
2023-07-07 |
Dnarx公司 |
用于体内核酸表达的系统和方法
|
|
TWI626309B
(zh)
*
|
2017-03-31 |
2018-06-11 |
國立清華大學 |
大量表現目標蛋白系統及其方法
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
CN111094330A
(zh)
|
2017-07-03 |
2020-05-01 |
转矩医疗股份有限公司 |
编码免疫刺激融合分子的多核苷酸及其用途
|
|
CA3069880A1
(en)
|
2017-07-17 |
2019-01-24 |
Spark Therapeutics, Inc. |
Apheresis methods and uses
|
|
WO2019123414A1
(en)
|
2017-12-22 |
2019-06-27 |
Straximm Llp |
Engineered viruses expressing cyclic gmp-amp synthase
|
|
CN111868077A
(zh)
|
2018-01-17 |
2020-10-30 |
南特生物公司 |
Gpi锚定抗原的增强的免疫原性
|
|
WO2019199689A1
(en)
|
2018-04-09 |
2019-10-17 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions comprising a viral vector for expression of a transgene and an effector
|
|
WO2020014523A1
(en)
*
|
2018-07-12 |
2020-01-16 |
Rocket Pharmaceuticals, Ltd. |
Gene therapy vectors for treatment of danon disease
|
|
US20210196771A1
(en)
|
2018-08-16 |
2021-07-01 |
Systems Oncology, Llc |
Recombinant myxoma viruses and uses thereof
|
|
MX2021006922A
(es)
*
|
2018-12-11 |
2021-09-30 |
Oncosec Medical Inc |
Constructo multigenico para la expresión de proteínas inmunoduladoras y métodos de uso.
|
|
CN113557242A
(zh)
|
2019-02-01 |
2021-10-26 |
得克萨斯大学体系董事会 |
用于治疗癌症的修饰的il-12 t细胞疗法
|
|
US20220403414A1
(en)
|
2019-10-16 |
2022-12-22 |
Wuxi Apptec (Shanghai) Co., Ltd. |
Novel aav variant
|
|
JP2023500337A
(ja)
|
2019-11-04 |
2023-01-05 |
イノビオ ファーマシューティカルズ，インコーポレイティド |
脳がんを治療するための併用療法
|
|
WO2021091560A1
(en)
|
2019-11-07 |
2021-05-14 |
Baylor College Of Medicine |
Oncolytic virotherapy and immunotherapy
|
|
US20240076689A1
(en)
|
2020-05-17 |
2024-03-07 |
Boehringer Ingelheim International Gmbh |
Viral vectors and nucleic acids for regulated gene therapy
|
|
US20230227847A1
(en)
|
2020-05-27 |
2023-07-20 |
Universität Zürich |
Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
|